Search
SOLACI Congress
HomeStructural heart diseaseValvular Aortic Valve

Valvular Aortic Valve

View Category
Other

TRI-SPA Study: Tricuspid Edge-to-Edge Treatment

Tricuspid regurgitation (TR) is a condition associated with high morbidity and mortality. Currently, surgery is the recommended...
Dr. Carlos Fava -
Learn More
Structural heart disease

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher...
Dr. Omar Tupayachi -
Learn More
Structural heart disease

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic...
Dr. Andrés Rodríguez -
Learn More
Coronary disease

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary...
Dr. Omar Tupayachi -
Learn More
Mitral valve

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has...
Dr. Carlos Fava -
Learn More
Structural heart disease

TCT 2024 – EVOLVED trial: Early Intervention for Patients with Severe Asymptomatic Aortic Stenosis and Myocardial Fibrosis?

Treating symptomatic severe aortic stenosis (AS) with aortic valve replacement is currently considered a class I recommendation,...
Dr. Andrés Rodríguez -
Learn More
Structural heart disease

TCT 2024 – TAVR UNLOAD: Moderate Aortic Stenosis with Ventricular Function Deterioration

The prevalence of aortic stenosis (AS) is on the rise in developed countries, and the link between...
Dr. Carlos Fava -
Learn More
Structural Heart Disease

TCT 2024 – EVOLVED Trial: Severe Aortic Stenosis and Myocardial Fibrosis

Severe aortic stenosis is increasingly common, especially in developed countries, and the current treatment of choice is...
Dr. Carlos Fava -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

Dr. Omar Tupayachi - 0
TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...

Long Term Results of the International Chimney Registry

Dr. Omar Tupayachi - 0
The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

Dr. Omar Tupayachi - 0
The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

Institutional News

Hemodynamics and Interventional Cardioangiology Hybrid Training Course SOLACI-CACI

solaci - 0
We are now open for registration to the hybrid training course on Hemodynamics and Interventional Cardioangiology for Technicians and Nurses SOLACI-CACI 2025 Find all course...

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy